NCT05604690View on ClinicalTrials.gov

Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

August 9, 2023

Study Completion Date

January 15, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

Avacc 10

Intranasal application of either low dose or high dose of Covid 19 vaccine.

COMBINATION_PRODUCT

Outer Membrane Vesicles (OMV) : OMV alone in vehicle

OMV will be administered via intranasal route.

OTHER

Placebo

Placebo will be administered via intranasal route.

Trial Locations (1)

4556

University of the Sunshine Coast Clinical Trial Centre, Sippy Downs

Sponsors

Lead Sponsor

Intravacc B.V.
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Intravacc B.V.

INDUSTRY